Neurohumoral transmission

Drug Benefits and Risks: International Textbook of Clinical Pharmacology

Volumn , Issue , 2008, Pages 289-310

  Pfaffendorf, Martin ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880186283     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (38)

1. Asplund R. Pharmacotherapy for nocturia in the elderly patient. Drugs Aging 2007;24(4):325-43. Review.
2. Begg E. Instant clinical pharmacology. Oxford: Blackwell Publishers; 2003.
3. Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007;30(5):194-202.
4. Booij LH. Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents. B Pharm World Sci 1997;19(1):13-34.
5. Brunton L, Lazo J, Parker K, editors. Goodman & Gilman's the pharmacological basis of therapeutics. Mather (CA): McGraw-Hill; 2005.
6. Burstein ES, Spalding TA, Brann MR. Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 1997;51(2):312-9.
7. Colli E, Digesu GA, Olivieri L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 2007;16:999-1007.
8. Colquhoun LM, Patrick JW. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv Pharmacol 1997;39:191-220.
9. Fillenz M. Noradrenergic neurons. Cambridge: Cambridge University Press; 1990.
10. Finley JC, O'Leary M, Wester D, MacKenzie S, Shepard N, Farrow S, Lockette W. A genetic polymorphism of the alpha2-adrenergic receptor increases autonomic responses to stress. J Appl Physiol 2004;96(6):2231-9.
11. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999;94:869-77.
12. Hein L, Kobilka BK. Adrenergic receptor signal transduction and regulation. Neuropharmacology 1995;34:357-66.
13. Helmer H. Frequently asked questions on tocolytics. BJOG, 2005;112 Suppl 1:94-6.
14. Hieble JP, Bondinell WE, Ruffolo RR Jr. a- and ß- adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem 1995;38:3415-44.
15. Hulme EC, Birdsall NJM, Bickley NJ. Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 1990;30:633-73.
16. Insel PA. Adrenergic receptors - evolving concepts and clinical implications. N Engl J Med 1996;334:580-5.
17. Jaillon P, Simon T. Genetic polymorphism of betaadrenergic receptors and mortality in ischemic heart disease. Therapie 2007;62(1):1-7.
18. Kaplan SA. a-Blocker therapy: current update. Rev Urol 2005;7 Suppl 8:S34-42.
19. Katzung BG, editor. Basic and clinical pharmacology. 10th ed. Norwalk (CN): Appleton and Lange; 2007.
20. Kügelgen I, Starke K. Noradrenaline-ATP co-transmission in the sympathetic nervous system. Trends Pharmacol Sci 1991;12:319-24.
21. Lam F, Gill P. ß-Agonist tocolytic therapy. Obstet Gynecol Clin North Am 2005;32(3):457-84.
22. Lyne SJ. The initiation and inhibition of labor - toward a molecular understanding. Semin Reprod Endocrinol 1994;12:284-97.
23. Menticoglou SM, Morrison I, Harman CR, Manning FA, Lange IR. Maximum possible impact of tocolytics in preventing preterm birth: a retrospective assessment. Am J Perinatol 1992;9:394-7.
24. Olson DM, Zakar T. Intrauterine tissue prostaglandin synthesis: regulatory mechanisms. Semin Reprod Endocrinol 1993;11:234-49.
25. Page CP, Hoffman B, Curtis M, Walker M. Integrated pharmacology. 6th ed. St Louis (MO) Mosby Inc; 2007.
26. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2005. Issue 3.
27. Pleger ST, Koch WJ. The yin and yang of increased betaadrenergic signaling: beta1-adrenergic genetic polymorphism and protection against acute myocardial ischemic injury. Am J Physiol Heart Circ Physiol 2006;290(4):H1408-9.
28. Rang HP, DaleMM, Ritter JM, Moore PK. Pharmacology. Edinburgh (UK): Churchill Livingstone; 2007.
29. Rossi S, editor. Australian medicines handbook. 2006 ed. Adelaide: Australian Medicines Handbook Pty Ltd; 2006.
30. Ruffolo RR Jr, Bondinell WE, Hieble JP. a- and ß- adrenoceptors: from the gene to the clinic. 2. Structureactivity relationships and therapeutic applications. J Med Chem 1995;38:3681-716.
31. Sargent PB. The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 1993;16:403-43.
32. Starke K, Göthert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 1989;69:864-989.
33. Summers RJ, McMartin LR. Adrenoceptors and their second messenger systems. J Neurochem 1993;60:10-23.
34. Sweetman S, editor. Martindale: the complete drug reference. 35th ed. London: Pharmaceutical Press; 2007.
35. Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 1994;34:281-320.
36. Tripathi KD. Essentials of medical pharmacology. 5th ed. New Delhi: Jaypee Brothers Medical Publishers; 2004.
37. Wessler I, Kirkpatrik CJ, Racke K. The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol 1999;26:198-205.
38. Whittaker VP, editor. The cholinergic synapse. Handbook of experimental pharmacology, vol 97. Berlin, Heidelberg: Springer-Verlag; 1988.